This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Trek Therapeutics, PBC

Drug Names(s): BI201335, BI-201335, BI 201335

Description: BI201335 is a HCV NS3 protease inhibitor (EC50 of 3-6 nM).

Deal Structure: Trek and Boehringer Ingelheim
In October 2015, Theravance announced that Trek Therapeutics has previously acquired Faldaprevir from Boehringer Ingelheim. Specifics on when the acquisition occurred was undisclosed.

Faldaprevir News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug